Last week Octopharma announced that Wilate has been approved by the FDA for treatment of bleeding episodes for all von Willbrand Disease patients. Plasma from U.S. FDA approved donation centers is used to make Wilate. A double viral inactivation process, solvent/detergent (S/D) process, as well as a dry heating process parts of the manufacturing and purification of Wilate. Wilate is Octapharma’s first blood coagulation drug in the United States ; Wilate is scheduled to be available in early 2010.